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Summary The pre-treatment cell kinetcis of 120 cervical tumours were assessed following the in vivo labelling
with the thymidine analogue Bromodeoxyuridine (BrdUrd). In 89% both static and temporal kinetic
parameters could be measured. Through the analysis of multiple biopsies from each tumour marked intra
tumour heterogeneity was demonstrated. The median values for the most highly labelled sample analysed for
each tumour were; S-phase duration (Ts) 12.1 h, BrdUrd labelling index (CLI) 9.5% and potential tumour
doubling time 4.4 days. There was a significant elevation in CLI, but no difference in Ts, between tumour and
non-neoplastic cervical tissue. There was also a significant elevation in CLI in advanced stage and large size
tumours. Although a significant elevation in CLI was found in aneuploid tumours this is likely to represent the
systemic bias of the calculation methods, with no difference being seen between aneuploid and diploid tumours
when BrdUrd labelling was measured with-out reference to the nuclei DNA content. The majority of these
patients were treated with radiotherapy and cell kinetic data will be correlated with treatment response when
adequate follow up has been achieved.
The rate at which a tumour proliferates is one of a number
of factors important in determining the response of the
tumour to cytotoxic therapy (Tubiana & Courdi, 1989). In
rapidly proliferating tumours the problem of tumour
repopulation between doses of radiotherapy, with resultant
treatment failure, has attracted recent attention due to the
potential therapeutic advantage of accelerated hyperfrac-
tionated radiotherapy (Fowler, 1986). Initial results from
studies involving altered radiotherapy scheduling and
measurement of cell kinetic have shown that patients with
rapidly proliferating tumours may benefit from accelerated
hyperfractionated schedules (Begg et al., 1992). The measure-
ment of tumour cell kinetics, particularly in tumours treated
with radiotherapy, has therefore gained a new significance,
with the possibility of tailoring radiotherapy schedules on the
tumour proliferation characterstics.
Many methods for the measurement of tumour prolifera-
tion have been introduced over the past 30 years, which in
itself indicates that no single technique developed to date has
been entirely satisfactory. Early methods involved the incor-
poration of tritiated thymidine into newly synthesised DNA,
therefore precluding their use in patients. Other approaches,
including S-phase analysis from DNA histograms, assessment
of proliferation associated antigens (for example Ki67) and
identification of AgNORs, are only able to define static
elements of proliferation, with no evaluation of phase dura-
tion. Through the incorporation of the thymidine analogue
bromodeoxyuridine (BrdUrd) in vivo, with delayed sampling
of the tumour, it is now possible to measure the duration of
S-phase in addition to the fraction of proliferating cells,
obtaining a more complete assessment of proliferation in vivo
than previously feasible (Begg et al., 1985). If this method of
proliferation assessment is to be of clinical value it is impor-
tant to determine the extent of tumour heterogeneity. This
paper reports the preliminary findings of a prospective study
measuring the pre treatment cell kinetics of cervical tumours
using the BrdUrd incorporation technique. Due to the acces-
sibility of cervical tumours, and the clinical feasibility of
obtaining multiple biopsies, we have been able to assess the
intra-tumour heterogeneity of S-phase duration and BrdUrd
labelling index.
Materials and methods
Selection ofpatients
Since April 1991 all patients with cervical carcinoma
scheduled for either a staging procedure prior to
radiotherapy or a radical hysterectomy have been asked to
give written consent for the administration of BrdUrd; 138
patients have agreed. The participating hospitals are The
Beatson Oncology Centre, Stobhill Hospital, and The Royal
Infirmary, Glasgow. Ethical Committee approval was given
for all hospitals.
Bromodeoxyuridine administration
BrdUrd was obtained from the Department of Pharmacy at
the University of Strathclyde. BrdUrd 200 mg was dissolved
in 100 ml of 0.9% saline and was administered intravenously
over 15 min. The infusion was given 6-8 h prior to the
predicted time of tumour sampling.
Tissue collection
Tumour samples were collected either from radical hysterec-
tomy specimens or by performing additional punch biopsies
at the time of the staging procedure, choosing macros-
copically viable areas of the tumour. When possible multiple
biopsies were obtained from different areas of the tumour. If
lymph node involvement was diagnosed, at time of hysterec-
tomy, samples of an involved lymph node were also collected
for kinetic evaluation. Tissue samples obtained were fixed
immediately in 70% alcohol for a minimum of 24 h. In 18
cases there was no macroscopic evidence of tumour at the
time of surgery. In these cases a biopsy from a part of the
cervix which appeared normal was performed.
Tissuepreparation
A small portion of each biopsy (approximately 50 mg) was
cut into 1 mm cubes using a scalpel, the remainder of the
sample was processed to wax, and a 5 micron section was
histologically examined to confirm the presence of tumour.
The minced samples were digested enzymatically for 30 min
in a 37°C agitating water bath using a 0.1% pepsin in 0.9%
saline solution at pH 1.5. The digest was washed in phos-
phate buffered saline (PBS) and syringed with a 22 gauge
needle to facilitate maximal disaggregation, before filtering
the sample through a 40 micron mesh.
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BrdUrd/DNA staining
The nuclear preparation was partially denatured with 2M
HCI for 30 min, then neutralised using 0.1 M borax. The
nuclei were then washed with PBS followed by PBS contain-
ing 1% bovine serum albumin and 0.1% tween 20, prior to
incubation with 0.1 ml mouse anti BrdUrd at a 1/30 dilution
for 60 min. (Dako Ltd., High Wycombe). Following two
washes with PBS, nuclei were incubated with 0.1 ml FITC
conjugated goat anti-mouse antibody at a 1/40 dilution for
30 min. (Sigma Chemicals Ltd., Poole). Both incubations
were performed at room temperature. After washing in PBS
twice, the nuclei were stained with 1 ml of propidium iodide
solution 10 ig ml-' for 30 min at room temperature.
Flow cytometric analysis
Samples were analysed on a Coulter Epics Profile II flow
cytometer. This has a single 15 mW argon laser emitting at
488 nm. Green and red fluorescent emissions were split using
a 550 nm dichroic mirror and collected through a 525 band
pass and a 610 long pass filter respectively. An appropriate
window was chosen from the DNA cytogram of area vs peak
signal to eliminate debris and aggregates of nuclei. 104-105
nuclei were analysed for each sample and the data was
collected in list mode. Using the Epics Profile II software a
DNA frequency histogram, a BrdUrd frequency histogram
and a DNA/BrdUrd cytogram were constructed.
Calculation ofbromodeoxyuridine labelling index
The total labelling index (TLI), representing the fraction of
the entire cell population labelled with Brdu, was determined
from the BrdUrd frequency histogram, the distinction between
positive and negative cells was determined visually (Figure 1).
A calculated labelling index (CLI%) was estimated from the
BrdUrd/DNA cytogram (Figure 2), by identifying labelling
associated with a specific tumour ploidy population, and by
compensating for those cells which have divided since labell-
ing (Begg et al., 1985).
The CLI% is given by the equation below:
Calculated labelling index = LuD + [LD x 0.5]
uL + LuD + [LD x 0.5]
where; LuD = labelled undivided cells
LD = labelled divided cells
uL = all unlabelled cells
Calculation ofS-phase (Ts) duration
The derivation of Ts assumes that at the time of labelling the
average DNA content of labelled cells lies mid-way between
the GI and G2 peaks. It also assumes that the progression of
cells through S-phase is constant. The average cell progres-
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Figure 2 DNA/BrdU cytogram (diploid tumour).
sion rate through S-phase can be calculated provided the
mean DNA content of labelled undivided cells and the time
interval between labelling and biopsy is known. All flash
labelled S-phase cells are expected to reach G2 by a time
equal to Ts, thus from the progression rate a value for Ts
can be derived.
There are two circumstances where Ts could not be cal-
culated. Firstly in some aneuploid tumours there was an
overlap of the S-phase labelled cells from the diploid and
aneuploid populations making calculation of the mean DNA
content of labelled undivided cells impossible. Secondly, in
samples with very low LI, only small numbers of labelled
undivided cells were identified. If analysis produced less than
300 labelled undivided cells the sample was repeated. In
practice this only proved to be a problem in samples contain-
ing no neoplastic tissue.
Calculated cell kinetic parameters
The potential doubling time was derived from the equation:
a)~ ~ ~ ~ T
Tpot= L T
CLI
L is a correction factor for the non-linear distribution of cells
through the cell cycle (Steel, 1977). We have used a constant
value of 0.8 in our calculations.
Analysis ofmultiple biopsies
A range of results was obtained for each tumour through the
analysis of multiple biopsies. The variance of results from
multiple biopsies from the same tumour was compared with
the variance of multiple analysis from a single biopsy. A
single biopsy was enzymatically digested as above and the
resultant suspension of nuclei was divided into ten aliquots.
Each sample was then processed and analysed separately,
two diploid and two aneuploid cell suspensions were
analysed for intra assay variation, with analysis of 40 ali-
quots in total.
For this purpose of correlation of cell kinetic data with
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tumour ploidy and clinical features, and in the calculation of
the summary statistics of the whole population, for each
tumour the biopsy with the greatest CLI% was selected.
Statistics
Kinetic parameters measured do not have a normal distribu-
tion therefore the Mann Whitney test and the Kruskal Wallis
test were used for comparison between two or more groups
respectively. The Spearman Rank Correlation was used for
comparison between tumour stage and kinetic data, and
Chi-squared test for comparison of ploidy status between
stages. Minitab statistical software was used for calculating
this data.
Results
variation for the GO/GI DNA peak ranged from 2.0 to
8.2%, with a mean of 4.1%. The proportion of aneuploid
and diploid tumours is shown in Figure 3a. There was no
statistical significant variation in the frequency of aneuploidy
with tumour stage (Chi Squared = 1.9, DF = 3, P = 0.59).
The frequency distribution for the DNA index is shown in
Figure 3b, the tumours are divided into ten groups, each
group representing an intervals of DNA index of 0.2. Multi-
ple aneuploid populations were present in six cases, in ten the
DNA/BrdUrd cytogram revealed equally elevated BrdUrd
labelling associated with diploid and aneuploid cell popula-
tions present, which was interpreted as representing a tumour
with a mixed ploidy population. If the diploid population
originated from normal stroma or lymphocytes this degree of
BrdUrd would not have been expected. In seven of these 10
tumours with diploid and aneuploid elements the aneuploid
population was in the tetraploid range.
A total of 138 patients with a pre-operative diagnosis of
cervical carcinoma have been injected with BrdUrd. No
immediate toxicity or adverse reactions have been noted. In
18 cases no neoplastic tissue was obtained at time of surgery,
in 15 ofthese a previous diagnostic cone biopsy had removed
all tumour. In two a diagnosis ofprimary bladder and in one
of primary rectal tumour was made intra operatively. In all
18 cases a biopsy of macroscopically normal cervix was
obtained and the absence of neoplastic tissue was confirmed
histologically. Of the 120 tumour samples obtained, 15 were
collected from patients scheduled for radical hysterectomy,
and 105 at time of the staging procedure.
Analysis ofploidy
The mean number of samples analysed per patient was 2.8
(range 1-6), the mean number of nuclei analysed for each
sample was 85,000 (range 20,000-100,000). Coefficient of
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Cell kinetic parameters
In 107 tumours (89.2%) there was adequate separation of
diploid and aneuploid elements to allow calculation of S-
phase duration (Ts) and calculated labelling index (CLI%),
the total labelling index (TLI%) could be calculated for all
tumours. Five cases where aneuploid and diploid tumour
elements were present, due to the small proportion of aneup-
loid nuclei, the diploid element was analysed in the assess-
ment of Ts and CLI%. Twelve of the eighteen cases where
samples did not contain neoplastic tissues Ts could not be
calculated due to inadequate numbers of labelled undivided
nuclei. The median values and quartile range for kinetic
parameters in tumour and non-neoplastic samples are shown
in Table I. There is a significant elevation in BrdUrd labell-
ing in tumour samples but no difference in Ts (P = 0.0001
and P = 0.72 respectively).
Intra tumour heterogeneity
The variation in cell kinetic parameters measured between
multiple biopsies from the same tumour was assessed for
those tumours where three or more biopsies were analysed
and in polyploid tumours where the ploidy of the analysed
population was the same in all samples. These criteria were
70.8% satisfied in 21 aneuploid and 22 diploid-tumours, a mean of
3.6 biopsies per patient were analysed, (range 3-6). Each
individual measurement for the tumour is expressed as a
fraction of the mean for this tumour. In the assessment of
intra assay variation each result was expressed as a ratio of
the mean for the ten aliquots analysed. The variation in Ts
and CLI% measurement seen between multiple biopsies of
the same tumour can not be explained by intra assay varia-
tion and therefore represent intra tumour heterogeneity,
(Table II). The variation in CLI% is greater than variation in
Ts measurement.
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Figure 3 a, Ploidy dependent on stage b, Tumour DNA index.
Cell kinetics and tumourploidy
A significant elevation in CLI% is seen in aneuploid tumours
(P = 0.002) but there is no difference in TLI or Ts, (Table
IV). There is however systematic bias in the measurement of
CLI% between diploid and aneuploid tumours due to the
admixture of normal cells with diploid tumours only. TLI%
measurement, although less precise, does not introduce this
bias. No difference in TLI between ploidy groups is seen
which suggests that for cervical tumours there is no increase
in BrdUrd labelling an aneuploid tumours.
Cell kinetics and clinicalparameters
A progressive elevation in CLI% is seen with advancing
stage (Spearman Rank Correlation r = 0.27, P= .005), no
variation in Ts was noted (Figures 4 and 5). A significant
decrease in the Tpot. was seen with increasing stage (Spear-
man Rank Correlation r = 0.27, P = .005). A similar increase
in TLI with tumour stage was also seen (r = 0.24, P= 0.008).
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Table I Cell kinetics of tumour and non-neoplastic tissue
Median Ts Median CLI Median Tpot
hours % days
Tumour n = 107 12.1 9.5 4.4
(Inter Quartile Range) (10.7-14.7) (6.2-14.7) (3.1-6.4)
Non-neoplastic n = 6 12.2 0.42 43.3
(Inter Quartile Range) (9.6-14.3) (0.2-0.8) (27.3-86.6)
P value 0.72 0.0001 0.0001
95% C.I. - 1.9 to 3.6 5.0 to 12.1 17.0 to 39.2
Table II Intra tumour heterogeneity
Standard deviation of Individual measurement
mean for twnour
Ts CLI% Tpot.
Tumour samples
Aneuploid n= 76 14.0% 19.8% 18.4%
(21 tumours)
Diploid n = 80 12.7% 30.0% 34.2%
(22 tumours)
Intra Assay Variation
Aneuploid n =20 3.1% 2.6% 5.2%
(2 tumours)
Diploid n=20 1.8% 2.5% 3.5%
(2 tumours)
Table III Cell kinetics and clinical parameters
Median Ts Median CLI Median Tpot.
hours % days
Size
<5cm n=55 11.7 9.0 4.9
>5cm n=52 12.5 11.7 4.0
P value 0.15 0.04 0.08
95% C.I. -1.9 to 0.3 0.1 to 4.4 -0.01 to 1.6
Lymph node
status
positive n=4 10.1 6 6.7
negative n= 11 12.6 6.6 6.3
P value 0.13 0.95 0.56
95% C.I. - 1.5 to 10.4 -5.2 to 7.1 -3.1 to 9.2
Age
>55 (n= 50) 12.4 9.4 4.5
45-55 (n= 14) 12.4 11.7 4.0
<45 (n= 14) 11.8 8.6 3.8
P value 0.14 0.51 0.55
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Spearman rank correlation R = 0.27, P = 0-005
An increase in CLI% is also observed in tumours of > 5 cm
size compared with tumours <5 cm (P = .04), but again no
difference in Ts was noted (Table III). To determine the
effect of patients age on tumour cell kinetics all women with
stage 2B, or more advanced tumours, were analysed follow-
ing division into three age groups, <45, 45-55, and >55.
No difference is seen in any of the kinetic parameters
measured between these groups, (Table III).
The relationship between the cell kinetics of the primary
tumour and the chance of metastatic disease was analysed in
the group of patients who were scheduled for a radical
hysterectomy and pelvic lymphadenectomy. Four out of
fifteen had histologically proven lymph node metastatic
deposits, in three of these four, biopsies from primary and
metastatic tumour were obtained. There was no significant
difference in the primary tumour cell kinetics dependent on
the presence of lymph node involvement, (Table III). Three
of four tumours with lymphatic involvement were diploid,
and ploidy of primary and secondary tumour was the same
in all cases. No consistent difference in kinetic parameters
was seen between the primary and secondary tumour.
Discussion
The study of human tumour cell kinetics has been facilitated
by the use of halogenated pyrimidines to label proliferating
cells. In addition to the advantage of being able to safely
label tumours in vivo, measurement of cell cycle phase dura-
tion (Ts) and calculation of Tpot, is now feasible. In a recent
review of over 600 tumours labelled with BrdUrd, variation
in Ts was almost as great as variation in LI, suggesting that
it may be an important parameter (Wilson, 1991). Due to the
relatively recent introduction of these techniques into clinical
studies little data are available at present to correlate the
temporal and static proliferation parameters measured with
long term survival.
A number of studies have evaluated proliferation status in
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Table IV Cell kinetics and tumour ploidy
Median Ts Median CLI Median TLI Median Tpot.
hours % % days
Tumour ploidy
Aneuploid n = 67 12.5 11.6 8.6 4.0
Diploid n=40 11.8 7.4 7.8 5.3
P value 0.27 0.002 0.61 0.01
95% C.I. -0.5 to 1.8 1.2 to 5.4 -2 to 1.4 0.25 to 2.1
cervical tumours with conflicting results regarding the cor-
relation of proliferation status to survival or recurrence rate.
Two have reported an increased short term recurrence rate in
tumours with high S-phase rates, whereas two others did not
confirm this effect in tumours with a high tritiated thymidine
labelling or in tumours with elevated Ki67 expression (Strang
et al., 1987; Naus & Zimmerman, 1991; Dixon et al., 1977;
Cole et al., 1992). None of these studies however have ade-
quately addressed the problem of intra tumour heterogeneity
or described the range of values obtained by multiple sampl-
ing of tumours. Our assessment of static and temporal kinetic
parameters, performed in vivo, with analysis ofmultiple biop-
sies gives a more complete assessment of cervical tumour
proliferation than any previous study.
These preliminary results demonstrate that measurement of
cell kinetics using BrdUrd is feasible in cervical tumours. In
all cases studied a value for total BrdUrd labelling (TLI)
could be calculated, and in 89% both temporal and static
parameters could be assessed. Cervical tumours do however
show marked intra tumour heterogeneity. In aneuploid
tumour, where analysis should not be affected by varying
proportions ofnormal tissue contamination, a wide spread of
values for CLI and Ts were obtained from multiple samples
from the same tumour. The difference is variation in
measured CLI% between diploid and aneuploid tumours is
likely to represent the inability of this technique to
differentiate normal from tumour cells in diploid tumours,
rather than representing greater heterogeneity in diploid
tumours. The degree of variation in cell kinetic seen in this
study emphasises that inadequacies of proliferation studies
based on the analysis of single samples and may be a major
limitation in the clinical application of results obtained from
tumour proliferation studies.
Values for Ts, LI and Tpot obtained in this study are
comparable with results obtained by Bennington following in
vivo labelling with tritiated thymidine and Wilson et al., using
similar BrdUrd incorporation techniques (Wilson, 1991; Ben-
nington, 1969). The wide range ofpotential tumour doubling
times observed amphasises the possible advantages for the
treatment of cervical tumours with accelerated or hyperfrac-
tionated radiotherapy schedules, provided an accurate
representative assessment of tumour proliferation can be
made.
The elevation in LI in advanced stage disease and in large
tumours seen in this study, may occur as a result ofevolution
of the tumour cell kinetics as progression occurs. Another
possible interpretation of these findings is that clinical stage
at diagnosis is related to the biological properties of the
tumour, with advanced stage, large tumours representing a
more proliferative group.
The presence of aneuploid cell populations in a number of
tumour types is associated with higher LI and poor prognosis
(Tribukait, 1984; Dressler et al., 1988). The comparison of
CLI% between aneuploid and diploid tumours is not valid
because of the inherent systematic bias due to the inclusion
of non-tumour cells within diploid samples. The similar TLI
seen in both diploid and aneuploid tumours indicates that
there is no difference in cell proliferation between ploidy
types. This conclusion has been supported by the finding of a
simular median BrdUrd labelling index determined from
immunohistochemical staining of tissue sections for diploid
and aneuploid tumours (unpublished data). The apparent
lack of proliferative advantage in aneuploid cervical tumours
may explain the variable results obtained when comparing
ploidy with survival in this tumour type, with a number of
studies failing to show a survival advantage for a particular
ploidy group (Hendy-Ibis et al., 1987; Davis et al., 1989;
Kenter et al., 1990).
Prolongation of S-phase has been noted in cancer cells
(Steel, 1977). Comparison of tumour with non-neoplastic
tissues in this study showed no alteration in Ts. The majority
of non neoplastic cervical tissue analysed in this study
originated from cervices in which a previous diagnostic
biopsy had removed all tumour (15/18), and in addition in
only 1/3 of these samples could values for Ts and CLI be
calculated, these results therefore may not be representative
of the whole group. The value for kinetic parameters
obtained may therefore not accurately reflect that of normal
cervix. By obtaining cervical biopsies from patients with
ovarian tumours who have received BrdUrd we hope to
obtain a more confident assessment of normal cervical cell
kinetics.
The determination of tumour ploidy is facilitated by
analysis of the BrdUrd/DNA cytogram. A group of patients
with tumours in which both diploid and aneuploid tumour
elements exist may be identified. The existence of this ploidy
variation has been noted previously in tumour karyotype
studies (Tribukait, 1984). If the diploid tumour cells only
constitute a small proportion of the tumour cells present, or
if the diploid tumour proliferation rate is low, the BrdUrd/
DNA cytogram will be unable to detect the presence of
diploid tumour element. The frequency of combined aneup-
loid diploid tumours is therefore likely to be higher than the
8% measured here. This ploidy variation is frequently not
reported in simple DNA histogram analysis.
The prognostic powers of kinetic data calculated using
BrdUrd incorporation techniques can only be accurately
assessed when clinical follow-up data are available. Cell kinetic
data will only be of prognostic value if it can predict prog-
nosis independently of existing known prognostic variables.
Comparison of the data obtained with accepted prognotic
indicators is therefore of limited value. We have presented a
basic analysis of the data with no attempt to correct for
associations between stage, size and age. The proportion of
tumour cells actively proliferating, but not S-phase duration,
appears to be related to the local growth of the tumour, with
a significant difference in LI, but not Ts, being seen between
tumour stages and between small and large tumours. Cell
kinetics of the primary tumour however appear unrelated to
the incidence of lymphatic involvement, with no difference in
kinetic parameters measured, dependant on the presence of
lymph node involvement at the time of radical hysterectomy
and pelvic lymphadenectomy. The debate regarding the pos-
sible poor prognosis of young women with cervical tumours
remains inconclusive (Peel et al., 1991). This study was
unable to show a difference in kinetic parameters dependent
on age. We do intend to compare single pathological review
of all tumours with kinetic parameters measured.
For advanced tumours, in addition to receiving conven-
tional radiotherapy, where appropriate, patients are entered
into a phase three study of neo-adjuvant chemotherapy.
Analysis of radiotherapy and chemotherapy response in rela-
tion to pre treatment tumour cell kinetics will therefore be
available in the next few years when adequate follow-up data
has been collected. We will also be able to assess the relative
importance of mean and maximum values obtained from
multiple tumour samples and hope to be able to provide
clinical guidelines relating to optimal cervical tumour sampl-
ing for the measurement of tumour cell kinetics.CELL KINETICS OF CERVICAL TUMOURS 171
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